drugset / Trial / NCT01570205
Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of the study is to investigate safety, tolerability, and pharmacokinetics of XG-102 following iv infusion of single escalating dose of 10, 40, and 80 µg/kg XG-102 to healthy male volunteers
Timeline
- Start
- 2011-07
- Primary completion
- 2011-11
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BRIMAPITIDE | Protein / enzyme biologic | 10 ug/kg | Intravenous |
| Subject | BRIMAPITIDE | Protein / enzyme biologic | 40 ug/kg | Intravenous |
| Subject | BRIMAPITIDE | Protein / enzyme biologic | 80 ug/kg | Intravenous |
Indications
No indication recorded.